Health resource utilization and associated healthcare costs of biologic disease modifying antirheumatic drugs in German patients with psoriatic arthritis-Reference-Cited by-同舟云学术

Health resource utilization and associated healthcare costs of biologic disease modifying antirheumatic drugs in German patients with psoriatic arthritis

Published:2021-03-20 Issue: Volume: Page:
ISSN:2151-464X
Container-title:Arthritis Care & Research
language:en
Short-container-title:Arthritis Care & Research

Author:

Sewerin Philipp¹^ORCID,Borchert Kathrin²,Meise Dominic²,Schneider Matthias¹,Mahlich Jörg³⁴

Affiliation:

1. Department and Hiller Research Unit for Rheumatology UKD, Heinrich‐Heine University Düsseldorf Germany

2. Xcenda GmbH Hannover Germany

3. Health Economics and Outcomes Research Janssen, Pharmaceutical Companies of Johnson & Johnson Neuss Germany

4. Düsseldorf Institute of Competition Economics (DICE) University of Düsseldorf Germany

Publisher

Wiley

Subject

Rheumatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/acr.24598

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: An Updated Systematic Literature Review;PharmacoEconomics;2024-08-24

2. Difficult-to-treat psoriatic arthritis (D2T PsA): a scoping literature review informing a GRAPPA research project;RMD Open;2024-01

3. Psoriasisarthritis: Welche Kostenbelastungen verursachen Biologika?;Aktuelle Rheumatologie;2023-04

4. Incidence of graft-versus-host-disease in Germany: evidence from health care claims data;Journal of Public Health;2022-08-08

5. Treatment Pathways and Health Outcomes of German Patients with Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation: A Retrospective Health Claims Data Analysis;Drugs - Real World Outcomes;2022-07-02